On August 9, 2023, ImmunoPrecise Antibodies Ltd announced that it has issued a statement in response to the filing made on July 7, 2023, by Ingalls & Snyder LLC, stating that the Company?s Board of Directors and management team value constructive input and welcome open communication with shareholders including Ingalls & Snyder, committed to acting in the best interest of the Company and strive to have the optimal board of directors? composition to attain Company?s strategic priorities and to maximize long-term shareholder value, and had opened the dialogue with Ingalls & Snyder LLC and will continue to engage in discussions with them as we carefully consider their views.